Systematic Exploration of Privileged Warheads for Covalent Kinase Drug Discovery

Kinase-targeted drug discovery for cancer therapy has advanced significantly in the last three decades. Currently, diverse kinase inhibitors or degraders have been reported, such as allosteric inhibitors, covalent inhibitors, macrocyclic inhibitors, and PROTAC degraders. Out of these, covalent kinase inhibitors (CKIs) have been attracting attention due to their enhanced selectivity and exceptionally strong affinity. Eight covalent kinase drugs have been FDA-approved thus far. Here, we review current developments in CKIs. We explore the characteristics of the CKIs: the features of nucleophilic amino acids and the preferences of electrophilic warheads. We provide systematic insights into privileged warheads for repurposing to other kinase targets. Finally, we discuss trends in CKI development across the whole proteome.

1. 1
   Progress with covalent small-molecule kinase inhibitors

   Drug Discovery Today2018200 citationsDataRank 0.795
2. 2
   Determining Cysteines Available for Covalent Inhibition Across the Human Kinome

   Journal of Medicinal Chemistry2017120 citationsDataRank 0.719
3. 3
   Harnessing systematic protein–ligand interaction fingerprints for drug discovery

   Drug Discovery Today202235 citationsDataRank 0.538
4. 4
   Advances in reversible covalent kinase inhibitors

   Medicinal Research Reviews20249 citationsDataRank 0.345
5. 5
   Exploring Extended Warheads toward Developing Cysteine-Targeted Covalent Kinase Inhibitors

   Journal of Chemical Information and Modeling20242 citationsDataRank 0.165